Dark

KTTA
Pasithea Therapeutics Corp. Common Stock
stock NASDAQ

At Close

May 9, 2025 3:59:30 PM EDT

0.8311USD-13.432%(-0.1290)2,062,518

0.00Bid 0.00Ask 0.0000Spread

Pre-market

May 9, 2025 9:28:30 AM EDT

0.9590USD-0.104%(-0.0010)76,597

After-hours

May 9, 2025 4:50:30 PM EDT

0.8200USD-1.330%(-0.0111)10,381

OverviewHistoricalExchangesShortsNews

Jan 26, 2022

08:12AM EST Pasithea Therapeutics Announces Opening Of Mental Health Clinic In Los Angeles And Broadens Focus Beyond Ketamine Treatments Benzinga

08:00AM EST Pasithea Therapeutics Announces Opening of Mental Health Clinic in GlobeNewswire Inc

Dec 30, 2021

09:37AM EST 2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around? Benzinga

Dec 27, 2021

10:20AM EST Mid-Morning Market Update: Markets Open Higher; News Corp To Buy Base Chemicals Benzinga

Dec 23, 2021

10:38AM EST EXCLUSIVE: Pasithea Therapeutics CEO Says 'We're working to have some big announcements in Q1 and we are hoping the market understands the optimal position where we stand at the moment' Benzinga

10:38AM EST EXCLUSIVE: Pasithea Therapeutics CEO Notes Co.'s Stock Has Been 'trading well below our cash per share,' Highlights 'buy recommendation by EF Hutton coverage of $3.50 per share' Benzinga

10:38AM EST EXCLUSIVE: Pasithea Therapeutics CEO, When Asked About Price Action In Stock (Shares Up 30% Thursday), Says Co. Did Not Release Any News Yesterday Benzinga

10:26AM EST Pasithea Therapeutics Spikes RTTNews

Dec 21, 2021

08:00AM EST Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the GlobeNewswire Inc

07:30AM EST EXCLUSIVE: Pasithea Therapeutics' Pasithea Has Opened Its Second London Clinics Offering Intravenous (IV) Ketamine Therapy To Patients Benzinga

Dec 14, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2021 Benzinga

08:33AM EST EF Hutton Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3.25 Benzinga

Dec 1, 2021

08:00AM EST -- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- GlobeNewswire Inc

07:31AM EST EXCLUSIVE: Pasithea Therapeutics Expands Its Ketamine Therapy Mobile Clinics Into Florida, Nevada Benzinga

07:30AM EST Pasithea Therapeutics' Wholly Owned Subsidiary Pasithea Clinics Expands Its Mobile Clinics Into Florida And Nevada Benzinga

Nov 29, 2021

05:45PM EST Pasithea Therapeutics Corp. Announces Closing of $30.4 Million GlobeNewswire Inc

Nov 24, 2021

03:04PM EST Mid-Afternoon Market Update: Dow Falls 75 Points; Biofrontera Shares Spike Higher Benzinga

12:32PM EST Mid-Day Market Update: Gap Drops Following Downbeat Q3 Results; Ocuphire Pharma Shares Jump Benzinga

09:18AM EST Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 24, 2021: KTTA, APVO, TSLA, BFRI, OCUP Benzinga

08:54AM EST Pasithea Therapeutics Corp. Prices 8.68M Share Private Placement At $3.50/Share Benzinga

08:53AM EST Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million GlobeNewswire Inc

Nov 23, 2021

02:31PM EST Mid-Afternoon Market Update: Dow Surges 100 Points; Zoom Video Shares Plunge Benzinga

01:35PM EST Ault Global Holdings Founder Tweets '"Today we sold all 390,000 shares of $KTTA and 390,000 $KTTAW we owned for a very nice win" sold through our subsidiary. $DPW' Benzinga

12:32PM EST Mid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge Benzinga

11:54AM EST EXCLUSIVE: Pasithea Therapeutics CEO, Tiago Reis Marques Says Co Is Looking Into Expand Its Business Internationally, Says Co Is Looking To Enter To The European Union In The Future Benzinga

11:52AM EST EXCLUSIVE: Pasithea Therapeutics CEO, Tiago Reis Marques Says Co's Primely Focus Is On Drug Development, Says 'As We Move Forward In Our Process We Might Look Into Raise More Money To Finance Our Drug Development Process In The Future' Benzinga

11:46AM EST EXCLUSIVE: Pasithea Therapeutics CEO, Tiago Reis Marques Now Interviewing On Benzinga Live Tv Benzinga

11:00AM EST EXCLUSIVE: Pasithea Therapeutics CEO, Tiago Reis Marques To Appear On Benzinga Live Tv At 11:45 a.m. ET Benzinga

10:33AM EST Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings Benzinga

08:00AM EST Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic GlobeNewswire Inc

07:31AM EST EXCLUSIVE: Pasithea's Depression Treatment, Esketamine Nasal Spray Added In Clinic Offerings In UK Benzinga

07:30AM EST EXCLUSIVE: Pasithea Therapeutics' Subsidiary Pasithea Clinics Reports It Has Been Approved To Provide Esketamine Nasal Spray (SPRAVATO) For Treatment-Resistant Depression In Adults Benzinga

Nov 17, 2021

08:00AM EST -- Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disorders -- GlobeNewswire Inc

07:30AM EST EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities Benzinga

07:30AM EST EXCLUSIVE: Pasithea Therapeutics Says 'Ketamine, when used at sub-anesthetic doses, has been shown to be highly effective in treating some psychiatric disorders.' Benzinga

07:30AM EST EXCLUSIVE: Pasithea Therapeutics' Wholly Owned Subsidiary Pasithea Clinics To Launch In-Home Intravenous Ketamine Therapy In New York City, Los Angeles, San Diego, And San Francisco To Expand Its International Footprint Benzinga

Nov 11, 2021

08:02AM EST Pasithea Therapeutics Collaborates With Renowned Musician, Producer To Create Soundtracks For Ketamine Therapy Benzinga

08:00AM EST Pasithea Therapeutics Collaborates with Renowned Musician and GlobeNewswire Inc

Nov 9, 2021

08:00AM EST Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the formation of its Scientific Advisory Board (SAB) to be chaired by esteemed psychiatrist, Charles Nemeroff, M.D., Ph.D. GlobeNewswire Inc

Oct 27, 2021

09:01AM EDT EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients Benzinga

08:59AM EDT Pasithea Therapeutics Announces Treatment Of First Patients In The UK With Ketamine Infusion Therapy RTTNews

07:45AM EDT Pasithea Therapeutics Announces Successful Treatment of First GlobeNewswire Inc

07:16AM EDT EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients Benzinga

07:15AM EDT EXCLUSIVE: Pasithea Therapeutics's Subsidiary Pasithea Clinics Announces Successful Treatment Of First Patients In The UK With Ketamine Infusion Therapy Benzinga

Oct 18, 2021

01:37PM EDT Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation Benzinga

Oct 14, 2021

09:14AM EDT Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom Benzinga

07:45AM EDT -- Pasithea Clinics partners with ZEN Healthcare a network of health clinics in Central London to offer ketamine infusion therapy for the treatment of mental health disorders -- GlobeNewswire Inc

07:15AM EDT EXCLUSIVE: Pasithea Therapeutics Reports Its Clinics Subsidiary Partnered With ZEN Healthcare To Offer Intravenous Ketamine Therapy In Knightsbridge, London, UK Benzinga

07:15AM EDT EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK Benzinga

Oct 13, 2021

04:25PM EDT There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are Benzinga

01:38PM EDT EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK Benzinga

Oct 11, 2021

08:34AM EDT Pasithea, Evotec Ink Drug Development Pact Benzinga

08:20AM EDT Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement Benzinga

06:50AM EDT Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced the initiation of a new chemical entity (NCE) development program and namedEvotecas its NCE research partner. GlobeNewswire Inc

06:00AM EDT EXCLUSIVE: Pasithea Therapeutics To Enter Into A Drug Development Agreement With Evotec SE; No Terms Disclosed Benzinga

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:37AM EDT Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment Benzinga

Sep 30, 2021

10:20AM EDT From BZ's Small Cap Healthcare Conference: Pasithea Therapeutics CEO Dr. Tiago Reis Marques Highlights Partnership With The IV Doc In The US, Giving The Co. Exposure In The US Benzinga

10:18AM EDT From BZ's Small Cap Healthcare Conference: Pasithea Therapeutics CEO Dr. Tiago Reis Marques Says Co. Signed Partnership With Zen Healthcare In The UK, Which Provides Exposure In The UK Benzinga

10:16AM EDT From BZ's Small Cap Healthcare Conference: Pasithea Therapeutics CEO Dr. Tiago Reis Marques Says Co.'s Secondary Focus Is Clinical Partnerships To Deliver Ketamine Treatments Benzinga

10:15AM EDT From BZ's Small Cap Healthcare Conference: Pasithea Therapeutics CEO Dr. Tiago Reis Marques Says Co.'s Primary Focus Is Developing New Molecular Entities And/Or Novel Biologic Drugs Benzinga

10:09AM EDT From BZ's Small Cap Healthcare Conference: Pasithea Therapeutics CEO Dr. Tiago Reis Marques Now Presenting Live Benzinga

Sep 29, 2021

04:32PM EDT Pasithea Therapeutics Corp. To Present At The Benzinga Healthcare Small Cap Conference Benzinga

04:30PM EDT Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows: GlobeNewswire Inc

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 20, 2021

12:51PM EDT Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial Benzinga

Sep 17, 2021

04:05PM EDT Pasithea Therapeutics Corp. Announces Closing of $24.0 Million GlobeNewswire Inc

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 15, 2021

11:12AM EDT Pasithea Therapeutics Shares Open For Trade At $4; IPO Priced $5/Unit Benzinga

09:21AM EDT Pasithea Therapeutics Shares Will Open For Quote At 11 a.m. EDT, Expected To Open For Trade After 11:10 a.m. EDT; IPO Priced $5/Unit Benzinga

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Sep 14, 2021

09:44PM EDT Pasithea Therapeutics Prices IPO Of 4.80 Mln Units At $5.00/unit RTTNews

.dark-mode .RRxqTM{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .RRxqTM{ color: #333333; background-color: white; border: 2px solid #333333; }KTTAPasithea Therapeutics Corp. Common Stockstock NASDAQ

KTTA
Pasithea Therapeutics Corp. Common Stock
stock NASDAQ